Literature DB >> 8851612

Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model.

J G den Hollander1, J W Mouton, M P van Goor, F P Vleggaar, H A Verbrugh.   

Abstract

The kinetics of the postantibiotic effect (PAE) during one dosing interval of tobramycin against Staphylococcus aureus and Pseudomonas aeruginosa was investigated. We determined the PAE at different time points during this dosing interval of 12 h in an in vitro pharmacokinetic model simulating human pharmacokinetics in which the half-life of tobramycin was adjusted to 2.4 +/- 0.2 h. Using an enzymatic method to inactivate tobramycin, we determined PAEs in samples extracted from the model at 1, 5, 8, and 12 h, corresponding with tobramycin concentrations of 20, 5, 2, and 1 times the MIC for the test organism. The PAE decreased significantly from 2.5 h at 1 h to 0 h at 12 h. No change in MIC was observed for the strains during the experiments. We conclude that the PAE decreases with decreasing tobramycin concentrations during a 12-h dosing interval and completely disappears after the concentration has reached the MIC for the test organism. On the basis of these observations, the emphasis that is placed on the PAE in discussions about the optimal dosing interval in aminoglycoside therapy is questionable.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851612      PMCID: PMC163199     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Once-daily aminoglycoside therapy.

Authors:  D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone.

Authors:  E W ter Braak; P J de Vries; K P Bouter; S G van der Vegt; G C Dorrestein; J W Nortier; A van Dijk; R P Verkooyen; H A Verbrugh
Journal:  Am J Med       Date:  1990-07       Impact factor: 4.965

3.  In vitro postantibiotic effects following multiple exposures of cefotaxime, ciprofloxacin, and gentamicin against Escherichia coli in pooled human cerebrospinal fluid and Mueller-Hinton broth.

Authors:  J A Karlowsky; G G Zhanel; R J Davidson; S R Zieroth; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

Review 4.  Killing and regrowth of bacteria in vitro: a review.

Authors:  W A Craig; S C Ebert
Journal:  Scand J Infect Dis Suppl       Date:  1990

Review 5.  Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man.

Authors:  W A Craig
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

6.  Postantibiotic effect of aminoglycosides on gram-negative bacteria evaluated by a new method.

Authors:  B Isaksson; L Nilsson; R Maller; L Sörén
Journal:  J Antimicrob Chemother       Date:  1988-07       Impact factor: 5.790

7.  Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.

Authors:  I Odenholt-Tornqvist; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

8.  Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia.

Authors:  J E Kapusnik; C J Hackbarth; H F Chambers; T Carpenter; M A Sande
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

9.  In vivo postantibiotic effect in a thigh infection in neutropenic mice.

Authors:  B Vogelman; S Gudmundsson; J Turnidge; J Leggett; W A Craig
Journal:  J Infect Dis       Date:  1988-02       Impact factor: 5.226

10.  Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections.

Authors:  W A Craig; J Redington; S C Ebert
Journal:  J Antimicrob Chemother       Date:  1991-05       Impact factor: 5.790

View more
  5 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Samer Kabbara; Giao Vo; Amy N Schilling; Elizabeth A Coyle
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

3.  Duration and clinical relevance of postantibiotic effect in relation to the dosing interval.

Authors:  J G den Hollander; K Fuursted; H A Verbrugh; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 4.  Pharmacological considerations for the proper clinical use of aminoglycosides.

Authors:  Spyridon Pagkalis; Elpis Mantadakis; Michael N Mavros; Christina Ammari; Matthew E Falagas
Journal:  Drugs       Date:  2011-12-03       Impact factor: 9.546

5.  Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration.

Authors:  Johan W Mouton; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.